exRNAdisease

Entry Detail

---



General Information

Database ID: exR0081851 RNA Name: SND1 RNA Type: mRNA Chromosome: chr7 Starnd: + Coordinate: Start Site(bp): 127652194 End Site(bp): 128092609 External Links: ENSG00000197157

Disease Information

Disease Name: Fragile X Syndrome Disease Category: Congenital, Hereditary, and Neonatal Diseases and Abnormalities MeSH ID: D005600 Type: Diseases Category/Congenital, Hereditary, and Neonatal Diseases and Abnormalities Alias: Fragile X Syndromes//Syndrome, Fragile X//Syndromes, Fragile X//Marker X Syndrome//Marker X Syndromes//Syndrome, Marker X//Syndromes, Marker X//Mental Retardation, X-Linked, Associated With Marxq28//X-Linked Mental Retardation and Macroorchidism//X Linked Mental Retardation and Macroorchidism//Fragile X Mental Retardation Syndrome//Martin-Bell Syndrome//Martin Bell Syndrome//Syndrome, Martin-Bell//Fra(X) Syndrome//FRAXE Syndrome//FRAXE Syndromes//Syndrome, FRAXE//Syndromes, FRAXE//Mental Retardation, X-Linked, Associated With Fragile Site Fraxe//Fragile X-F Mental Retardation Syndrome//Mar (X) Syndrome//FRAXA Syndrome//FRAXA Syndromes//Syndrome, FRAXA//Syndromes, FRAXA

Expression Detail

GEO ID: GSE83556 Description: Global transcriptome dysregulation in second trimester fetuses with FMR1 expansions Experimental Design: Disease vs Control Case Disease Type: Fragile X Syndrome Case Disease SubType: NA Case Sample: Fragile X Syndrome Control Sample: Normal Number of Case: 22 Number of Control: 18 Number of Samples: 40

Regulatory Relationship

mRNA targets: Gene Symbol Chromosome Start Site(bp) End Site(bp) Strand ABCA1 chr9 104781006 104928155 - ABCF2 chr7 151207837 151227166 - AC005943.1 chr19 1578339 1605445 - AC010422.3 chr19 12643831 12648397 - AC011462.1 chr19 41350853 41425001 + AC020915.5 chr19 58228914 58315183 + AC073610.2 chr12 48903503 48957365 - AC092143.1 chr16 89919165 89936092 + AC124312.1 chr15 24955034 25000276 + AC245033.1 chr15 82536788 82573194 - ACTB chr7 5527148 5563784 - ACTR1B chr2 97655939 97664044 - ACTR2 chr2 65227753 65271253 + ADRM1 chr20 62302093 62308862 + ADSL chr22 40346500 40390463 + AGO1 chr1 35869808 35930532 + AGTRAP chr1 11736084 11754802 + AHCY chr20 34280268 34311802 - AL022238.4 chr22 40346529 40410054 + AL031708.1 chr16 1632259 1686715 + AL365205.1 chr6 41780349 41790141 + miRNA targets: miRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand hsa-miR-18a-5p chr13 91350756 91350778 + hsa-miR-302b-3p chr4 112648489 112648511 - circRNA targets: NA lncRNA targets: lncRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand AC245033.4 chr15 82533175 82540008 - AD000090.1 chr19 35557956 35581954 + AL049795.2 chr1 32170733 32176568 + Display:

Experiment Detail

GEO ID: GSE83556 Sample Source: Amniotic Fluid Source Fraction: Supernatant Platform: GPL570 Method: Microarray Num of detected RNA Type: 1 Num of detected RNAs of this Type: 17063 Sample treatment protocol: RNA was extracted from 5-15 mL amniotic fluid supernatant (centrifugation at 350g, 4C, 10, min). RNA Extract protocol: All samples were processed using the Qiagen Circulating Nucleic Acid kit with an on-column DNase digestion step to remove genomic DNA. The RNA was then purified and concentrated with the RNeasy MinElute Clean up kit and eluted in RNasefree water. RNA library preparation protocol: RNA was converted to cDNA and amplified using the Ovation Pico WTA kit V2 and then purified with the QIAquick PCR Purification kit. Samples were labeled using the Encore Biotin Module (NuGEN, San Carlos, CA)Samples were labeled using the Encore Biotin Module (NuGEN, San Carlos, CA).

Reference

PMID: NA Title: NA Author: NA Journal: NA Description: NA